What question did this study set out to answer?

To develop and validate a serum-based microRNA biomarker panel capable of accurately detecting gastric cancer in high-risk populations.

October 7, 2020Gut208 citationsOpen Access

Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population

To develop and validate a serum-based microRNA biomarker panel capable of accurately detecting gastric cancer in high-risk populations.
Clinical trial registered under ClinicalTrials.gov (NCT04329299).
Assayed serum microRNA expression signatures to construct and validate a multi-marker diagnostic panel.
Identified and validated a circulating microRNA biomarker signature associated with the presence of gastric cancer in high-risk individuals.
Demonstrated the clinical utility of serum-derived microRNA profiling as a noninvasive diagnostic tool for gastric malignancy screening.

This study is registered with ClinicalTrials.gov (Registration number: NCT04329299).

Ask AI

Helpful

Bookmark

View Full Paper

So et al. (2020) studied this question.

Ask AI

Helpful

Bookmark

View Full Paper

October 7, 2020Gut208 citationsOpen Access

To develop and validate a serum-based microRNA biomarker panel capable of accurately detecting gastric cancer in high-risk populations.
Clinical trial registered under ClinicalTrials.gov (NCT04329299).
Assayed serum microRNA expression signatures to construct and validate a multi-marker diagnostic panel.
Identified and validated a circulating microRNA biomarker signature associated with the presence of gastric cancer in high-risk individuals.
Demonstrated the clinical utility of serum-derived microRNA profiling as a noninvasive diagnostic tool for gastric malignancy screening.

This study is registered with ClinicalTrials.gov (Registration number: NCT04329299).

Ask AI

Helpful

Bookmark

View Full Paper

So et al. (2020) studied this question.

Ask AI

Helpful

Bookmark

View Full Paper